**Conreleve Capsule - Complete Product Documentation**

# Manufacturing Process

The following diagram illustrates the end-to-end manufacturing process.

We are planning to commence production of Conreleve capsules in January of next year. Initially, we will manufacture a batch of one million units over a three-month period. We are targeting a market launch for Conreleve by April of the following year.

## Fill Materials

The fill materials for the Conreleve capsule undergo careful weighing, screening, and blending processes. These fiSue Davill materials consist of both active pharmaceutical ingredients and inactive excipients, as detailed in the table below. Following the blending process, the fill materials undergo rigorous quality testing before being encapsulated.

|  |  |
| --- | --- |
| Component | Function |
| Proprietary formula x456 | Active pharmaceutical ingredient |
| Polydextrose | Stabilizing agent |
| Colloidal silicon dioxide | Anti-caking agent |

**Capsule Shell Composition**

The materials used to form the capsule shell itself are also weighed, sieved, and thoroughly mixed. These materials product history are then melted, shaped, and dried through specialized processes. Subsequently, they undergo comprehensive quality control testing before being used to encapsulate the fill materials.

**Clinical Efficacy**

Clinical trials have demonstrated significant pain relief benefits for patients suffering from various types of discomfort. In 95% of cases, Conreleve proved more effective than placebo treatments. (Clinical Trial 1) Only 3% of patients reported experiencing adverse effects after taking Conreleve. Nausea, bruising, and dizziness were among the reported side effects. (Clinical Trial 1)

# Product History

Researchers at Contoso Pharmaceutical Laboratory developed the active ingredient that comprises Conreleve four years ago. Contoso Pharmaceutical Laboratory initiated clinical trials three years ago. Regulatory authorities approved the use and marketing of Conreleve six months ago.

## Product Description

The medication is presented in the form of a turquoise and white capsule.

We utilize standard size #1 capsules. Each capsule weighs 75 mg and measures 16.61 mm in length. This capsule size can accommodate up to 400 mg of active material.

The primary packaging consists of a standard blister pack with an aluminum backing.

The secondary packaging is presented as a standard cardboard box.